SCHEMBL27385697

SCHEMBL27385697

CC(=O)C(=O)NCc1cc2cc(Cl)c(C)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP1A2 P05177 1/20 0.38
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
MTNR1A P48039 6/20 0.37
MTNR1B P49286 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27382975 0.83 CACNA1G (0.48) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27384177 0.81 SMN1; SMN2 (0.43) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27384105 0.80 SMN1; SMN2 (0.41) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27384649 0.79 HTT (0.42) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27383346 0.78 RAB9A (0.45) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27384009 0.78 SMN1; SMN2 (0.41) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL30946281 0.77 ALDH1A1 (0.41) SMN1; SMN2RAB9AMAPTMEN1KMT2A
SCHEMBL27382489 0.74 SMN1; SMN2 (0.47) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27246881 0.73 SMN1; SMN2 (0.46) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL27382677 0.72 RAB9A (0.48) SMN1; SMN2RAB9AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 WO disclosed